Videos

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the IMvigor Study, which looked at anti PD-1 agent atezolizumab in advanced urothelial carcinoma.

Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses recent updates in radiation therapy for breast cancer as discussed in the NCCN guideline.

James L. Mulshine, MD, professor, acting dean, Graduate College, Department of Internal Medicine, Rush Medical College, Rush University, discusses the worldwide differences in screening for lung cancer.

Laurie E. Gaspar, FASTRO, FACR, MD, MBA, professor and chair of the Department of Radiation Oncology, University of Colorado Denver, discusses the importance of enrolling patients with brain metastases on clinical trials.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering, discusses what is on the horizon for the use of PD-L1 agents in liver cancer.

mNSCLC with Mark Kris, MD and Mark Socinski, MD

mCRC with Tanios Bekaii-Saab, MD and Tara Seery, MD